UPDATE: Jefferies Downgrades NPS Pharmaceuticals on Valuation

In a report published Wednesday, Jefferies analyst Eun K. Yang downgraded the rating on NPS Pharmaceuticals NPSP from Buy to Hold, but reiterated the $38.00 price target. In the report, Jefferies noted, “FY14 guidance/4Q13 sales of Gattex preannounced on 1/8/14. Solid Gattex U.S. launch in 2013 and anticipation of bigger Natpara opportunity resulted in strong stock performance. Now trading at ~17.2x EV/'14 revenue (vs. ~16.1x for BMRN and ~17.5x for ALXN), we view near term, potential of Gattex/Revestive and Natpara is largely priced in. Thus, we downgrade NPSP to Hold on valuation and maintain $38 PT.” NPS Pharmaceuticals closed on Tuesday at $37.95.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorDowngradesAnalyst RatingsEun K. YangJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!